Leo Bustad
Cardiovascular Disease · Anchorage, AKNPI 1144245903
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 25.5% of the total. Reporting peaked in 2021 at $183 and has fallen 83.3% since, to $31 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in AK, where the typical reported total is $818.
Across 49 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$209
- Amgen$80
- E.r. Squibb & Sons, L.L.C.$65
- Novartis$52
- Pfizer$42
- Novo Nordisk$39
- plus $331 from 16 others
What the payments were for
- Food & beverage$818100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $209 |
| Amgen | 4 | $80 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65 |
| Novartis | 3 | $52 |
| Pfizer | 3 | $42 |
| Novo Nordisk | 3 | $39 |
| Boehringer Ingelheim | 2 | $34 |
| Cook Medical LLC | 2 | $33 |
| Lilly USA, LLC | 2 | $29 |
| Bard Peripheral Vascular, Inc. | 1 | $27 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Abbott | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Medtronic | 1 | $16 |
| Alkermes, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $11 |
| Merck | 1 | $11 |
How this compares
$818 in reported general payments places this provider in the 50th percentile of 26 cardiovascular disease providers in Alaska.
Other cardiovascular disease in Anchorage
- Suneet PurohitAnchorage$77K
- Ahmed AbuzaidAnchorage$77K
- Jeffrey DixsonAnchorage$2K
- Brian ScullyAnchorage$2K
- Mario BinderAnchorage$2K
- Hung VoAnchorage$1K
- William MayerAnchorage$1K
- Moyukh GhoshAnchorage$1K
- Scott EbenhoehAnchorage$658
- Linda IrelandAnchorage$415
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.